175 related articles for article (PubMed ID: 30126626)
1. Expert opinion on thyroid complications of new anti-cancer therapies: Tyrosine kinase inhibitors.
Drui D; Illouz F; Do Cao C; Caron P
Ann Endocrinol (Paris); 2018 Oct; 79(5):569-573. PubMed ID: 30126626
[TBL] [Abstract][Full Text] [Related]
2. Expert opinion on thyroid complications in immunotherapy.
Illouz F; Drui D; Caron P; Do Cao C
Ann Endocrinol (Paris); 2018 Oct; 79(5):555-561. PubMed ID: 30126627
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders.
Jannin A; Penel N; Ladsous M; Vantyghem MC; Do Cao C
Crit Rev Oncol Hematol; 2019 Sep; 141():23-35. PubMed ID: 31202955
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients.
Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
Thyroid; 2018 Apr; 28(4):437-444. PubMed ID: 29652599
[TBL] [Abstract][Full Text] [Related]
5. Thyroid dysfunctions induced by tyrosine kinase inhibitors.
Fallahi P; Ferrari SM; Vita R; Di Domenicantonio A; Corrado A; Benvenga S; Antonelli A
Expert Opin Drug Saf; 2014 Jun; 13(6):723-33. PubMed ID: 24821006
[TBL] [Abstract][Full Text] [Related]
6. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors.
Illouz F; Braun D; Briet C; Schweizer U; Rodien P
Eur J Endocrinol; 2014 Sep; 171(3):R91-9. PubMed ID: 24833135
[TBL] [Abstract][Full Text] [Related]
7. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
[No Abstract] [Full Text] [Related]
8. Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers.
Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
Thyroid; 2018 Apr; 28(4):445-453. PubMed ID: 29652597
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review.
Illouz F; Laboureau-Soares S; Dubois S; Rohmer V; Rodien P
Eur J Endocrinol; 2009 Mar; 160(3):331-6. PubMed ID: 19103722
[TBL] [Abstract][Full Text] [Related]
10. Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors.
Gabora K; Piciu A; Bădulescu IC; Larg MI; Stoian IA; Piciu D
Drug Metab Rev; 2019 Nov; 51(4):562-569. PubMed ID: 31718371
[TBL] [Abstract][Full Text] [Related]
11. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
[TBL] [Abstract][Full Text] [Related]
12. Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?
Sbardella E; Tenuta M; Sirgiovanni G; Gianfrilli D; Pozza C; Venneri MA; Cortesi E; Marchetti P; Lenzi A; Gelibter AJ; Isidori AM
Clin Endocrinol (Oxf); 2020 Mar; 92(3):258-265. PubMed ID: 31788837
[TBL] [Abstract][Full Text] [Related]
13. Thyroid dysfunction as an unintended side effect of anticancer drugs.
Torino F; Barnabei A; Paragliola R; Baldelli R; Appetecchia M; Corsello SM
Thyroid; 2013 Nov; 23(11):1345-66. PubMed ID: 23750887
[TBL] [Abstract][Full Text] [Related]
14. Endocrine-related adverse conditions induced by tyrosine kinase inhibitors.
De Leo S; Trevisan M; Moneta C; Colombo C
Ann Endocrinol (Paris); 2023 May; 84(3):374-381. PubMed ID: 36963756
[TBL] [Abstract][Full Text] [Related]
15. Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors.
Buffier P; Bouillet B; Smati S; Archambeaud F; Cariou B; Verges B
Ann Endocrinol (Paris); 2018 Oct; 79(5):574-582. PubMed ID: 30174137
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma.
Yavuz S; Apolo AB; Kummar S; del Rivero J; Madan RA; Shawker T; Reynolds J; Celi FS
Thyroid; 2014 Aug; 24(8):1223-31. PubMed ID: 24724719
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis.
Makita N; Iiri T
Thyroid; 2013 Feb; 23(2):151-9. PubMed ID: 23398161
[TBL] [Abstract][Full Text] [Related]
18. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Bailey EB; Tantravahi SK; Poole A; Agarwal AM; Straubhar AM; Batten JA; Patel SB; Wells CE; Stenehjem DD; Agarwal N
Clin Genitourin Cancer; 2015 Jun; 13(3):e131-7. PubMed ID: 25497584
[TBL] [Abstract][Full Text] [Related]
19. No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects.
Huang F; Ajavon A; Huang E; Lettieri J; Liu R; Peña C; Berse M
Thyroid; 2017 Sep; 27(9):1118-1127. PubMed ID: 28741453
[TBL] [Abstract][Full Text] [Related]
20. [Management of side-effects of targeted therapies in renal cancer: endocrine side-effects and metabolic disorders].
Caron P; Gravis G; Oudard S; Pignot G
Bull Cancer; 2011; 98(3 Suppl):S47-59. PubMed ID: 25819126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]